BRAF and cancer: Sorafenib is an orally active inhibitor of multiple kinases, including BRAF, VEGFR1, and VEGFR-2, which can inhibit cancer cell proliferation and angiogenesis.445,446 In the phase 3 DECISION study, sorafenib significantly improved the ORR (12.2% vs. 0.5%) and PFS (10.8 vs. 5.8 months) versus placebo in patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer.447 Most AEs were grade 1 or 2, and no unexpected AEs occurred.